ESR1 and breast carcinoma: The well‐documented anti‐tumor effects of bazedoxifene observed in models for ovarian (Romero et al, 2012) and tamoxifen‐resistant breast cancer (Wardell et al, 2013) have been mechanistically attributed to the capacity of bazedoxifene to compete with 17β‐estradiol for binding to ERα in these steroid‐sensitive tissues.